De Novo Hyperkalemia Increases Risks for Death, Hospitalizations
Even a single episode of hyperkalemia is associated with a major disease burden, a study finds.
Even a single episode of hyperkalemia is associated with a major disease burden, a study finds.
Nearly two-thirds of inpatients with a hyperkalemia diagnosis do not receive potassium binders, according to a contemporary analysis.
Nearly 74% of hemodialysis patients experienced pre-dialysis hyperkalemia within 1 year of enrollment in the Dialysis Outcomes and Practice Patterns Study, according to investigators.
Study findings support the potential clinical utility of laxatives for hyperkalemia management in patients with nondialysis-dependent CKD.
Modifying the potassium concentration used for dialysis may decrease mortality risk among hospitalized patients with end-stage kidney disease and severe hyperkalemia, according to investigators.
In a study, patients who experienced hyperkalemia while on a renin-angiotensin-aldosterone-system inhibitor had the lowest 1-year risk of recurrent hyperkalemia when the medication was discontinued.
Serum potassium levels prior to an acute hyperkalemia episode do not predict mortality, but following this episode, progression from normokalemia to hyperkalemia is significantly associated with an increase in mortality risk, a study found.
High visit-to-visit variability in kidney function and serum electrolyte indexes may identify subsets of patients who have heart failure with preserved ejection fraction who could benefit from more aggressive monitoring for clinical deterioration, according to investigators.
Higher potassium variability in patients with advanced CKD prior to starting dialysis may serve as a clinically important prognostic marker for mortality after transitioning to dialysis, according to investigators.
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.